- Home
- DFIN vs AKRO Comparison
DFIN vs AKRO Comparison
Compare DFIN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- AKRO
- Stock Information
- Founded
- DFIN 1983
- AKRO 2017
- Country
- DFIN United States
- AKRO United States
- Employees
- DFIN N/A
- AKRO N/A
- Industry
- DFIN Other Consumer Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- AKRO Health Care
- Exchange
- DFIN Nasdaq
- AKRO Nasdaq
- Market Cap
- DFIN 1.9B
- AKRO 2.0B
- IPO Year
- DFIN N/A
- AKRO 2019
- Fundamental
- Price
- DFIN $60.68
- AKRO $28.08
- Analyst Decision
- DFIN Strong Buy
- AKRO Strong Buy
- Analyst Count
- DFIN 3
- AKRO 8
- Target Price
- DFIN $76.33
- AKRO $46.83
- AVG Volume (30 Days)
- DFIN 220.6K
- AKRO 594.3K
- Earning Date
- DFIN 02-18-2025
- AKRO 02-27-2025
- Dividend Yield
- DFIN N/A
- AKRO N/A
- EPS Growth
- DFIN 18.18
- AKRO N/A
- EPS
- DFIN 3.18
- AKRO N/A
- Revenue
- DFIN $802,100,000.00
- AKRO N/A
- Revenue This Year
- DFIN $1.75
- AKRO N/A
- Revenue Next Year
- DFIN $4.27
- AKRO N/A
- P/E Ratio
- DFIN $19.71
- AKRO N/A
- Revenue Growth
- DFIN 1.74
- AKRO N/A
- 52 Week Low
- DFIN $56.02
- AKRO $15.32
- 52 Week High
- DFIN $71.01
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- DFIN 45.11
- AKRO 41.87
- Support Level
- DFIN $60.24
- AKRO $27.45
- Resistance Level
- DFIN $63.74
- AKRO $28.76
- Average True Range (ATR)
- DFIN 1.61
- AKRO 1.49
- MACD
- DFIN 0.08
- AKRO -0.12
- Stochastic Oscillator
- DFIN 16.28
- AKRO 17.98
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.